NEO NeoGenomics, Inc.

15.09USD-1.31%Mkt Cap: 1.95B USDP/E: —

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clin…

Institutional holders20 on file

Key Statistics

Company
Market Cap1.95B USD
Enterprise Value2.29B USD
Revenue (TTM)787.75M USD
Gross Profit314.29M USD
Net Income (TTM)-108.03M USD
Revenue/Share6.11 USD
Last Price15.09 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)47.97
PEG2.09
EV/EBITDA100.52
EV/Revenue2.90
P/S2.48
P/B2.43
EPS (TTM)-0.24 USD
EPS (Forward)0.31 USD
52W Range
7.07061% of range20.15
52W High20.15 USD
52W Low7.070 USD
Profitability
Gross Margin43.21%
Oper. Margin-5.47%
EBITDA Margin2.89%
Profit Margin-14.85%
ROE-12.91%
ROA-7.94%
ROIC-7.95%
ROCE-6.93%
Growth
Revenue Growth11.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF5.23M USD
CapEx (TTM)27.01M USD
FCF Margin0.61%
FCF Yield0.25%
Net Debt309.86M USD
Net Debt/EBITDA13.61
Net Debt/FCF64.53
Balance Sheet
Debt/Equity0.49
Current Ratio3.53
Quick Ratio3.04
Book Value/Sh6.20 USD
Cash/Share1.08 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)23.40 USD
Upside (mean)+55.1%
Target Range19.00 USD – 35.00 USD
19.00+55.1% to mean35.00
# Analysts10
Ownership
Shares Out.129.39M
Float117.92M
Insiders2.10%
Institutions111.70%
Short Interest
Short Ratio5.9d
Short % Float11.96%
Short % Out.10.15%
Shares Short13.13M
Short (prev mo.)14.15M
Technical
SMA 5017.51 (-13.8%)
SMA 20013.01 (+16.0%)
Beta1.83
S&P 52W Chg12.08%
Avg Vol (30d)1.66M
Avg Vol (10d)1.50M
Technical Indicators
RSI (14)36.3
MACD-0.4721
MACD Signal-0.2754
MACD Hist.-0.1966
BB Upper18.35 USD
BB Middle16.63 USD
BB Lower14.92 USD
BB Width20.60%
ATR (14)0.8355 USD
Vol Ratio (20d)1.05x

About NeoGenomics (NASDAQ: NEO)

›

NeoGenomics (NASDAQ: NEO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 2,500 employees.

The shares were at 15.09 USD on 19 November 2026, up 45.1% over 52 weeks. Its 52-week range is 7.070 USD to 20.15 USD: the price is 25.1% below the high and 113.4% above the low.

Its market capitalisation is 1.95B USD.

NeoGenomics reports return on equity of -12.9%, an operating margin of -5.5% and revenue up 11.4% year over year.

Its debt exceeds its cash by 309.86M USD, a debt-to-equity ratio of 0.49. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 10 analysts cover the stock; their mean price target of 23.40 USD is 55.1% above the current price. The next earnings report is expected on 16 February 2027.